Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (5)
Language
- English (5)
Keywords
- USP28 (2)
- lung cancer (2)
- 28 (1)
- ATM (1)
- CRISPR-Cas9 (1)
- Cisplatin (1)
- DNA-PK (1)
- IR (1)
- JUN (1)
- MYC (1)
- NOTCH (1)
- NSCLC (1)
- PI3K (1)
- PTEN (1)
- buparlisib (1)
- c-MYC (1)
- cancer (1)
- gefitinib (1)
- mouse model (1)
- non-small cell lung cancer (1)
- radiotherapy (1)
- squamous cell carcinoma (1)
- squamous tumors (1)
- vemurafenib (1)
- ∆Np63 (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Pathologisches Institut (4)
- Klinik und Poliklinik für Strahlentherapie (3)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Lehrstuhl für Biochemie (1)
- Medizinische Klinik und Poliklinik I (1)
The transcription factor ∆Np63 is a master regulator of epithelial cell identity and essential for the survival of squamous cell carcinoma (SCC) of lung, head and neck, oesophagus, cervix and skin. Here, we report that the deubiquitylase USP28 stabilizes ∆Np63 and maintains elevated ∆NP63 levels in SCC by counteracting its proteasome‐mediated degradation. Impaired USP28 activity, either genetically or pharmacologically, abrogates the transcriptional identity and suppresses growth and survival of human SCC cells. CRISPR/Cas9‐engineered in vivo mouse models establish that endogenous USP28 is strictly required for both induction and maintenance of lung SCC. Our data strongly suggest that targeting ∆Np63 abundance via inhibition of USP28 is a promising strategy for the treatment of SCC tumours.